Senescent cells in early vascular ageing and bone disease of chronic kidney disease—a novel target for treatment by Hobson, Sam et al.
toxins
Review
Senescent Cells in Early Vascular Ageing and Bone
Disease of Chronic Kidney Disease—A Novel Target
for Treatment
Sam Hobson 1, Samsul Arefin 1, Karolina Kublickiene 1, Paul G. Shiels 2 and Peter Stenvinkel 1,*
1 Division of Renal Medicine, Department of Clinical Science, Technology and Intervention, Karolinska
University Hospital, 14186 Stockholm, Sweden; sam.hobson@ki.se (S.H.); samsul.arefin@ki.se (S.A.);
karolina.kublickiene@ki.se (K.K.)
2 Institute of Cancer Sciences, MVLS, University of Glasgow, Glasgow G61 1QH, UK;
paul.shiels@glasgow.ac.uk
* Correspondence: peter.stenvinkel@ki.se; Tel.: +46-8-585-82532
Received: 31 December 2018; Accepted: 24 January 2019; Published: 1 February 2019


Abstract: Together with bone-mineral disorders, premature vascular ageing is a common feature of the
uremic phenotype. A detailed understanding of mechanisms involved remains unclear and warrants
further research. Available treatment options for end stage renal disease are principally dialysis and
organ transplantation, as other treatment alternatives have proven insufficient. Chronic kidney disease
(CKD) has been proposed as a model of early vascular and bone ageing, with accumulating evidence
supporting the contribution of cellular senescence and the senescence-associated secretory phenotype
(SASP) to cardiovascular pathology in CKD. Correspondingly, novel therapies based around the use of
senolytic compounds and nuclear factor-erythroid-2-related factor 2 (Nrf2) agonists, have been suggested
as attractive novel treatment options. In this review, we detail the contribution of the uremic environment
to these processes underpinning ageing and how these relate to vascular health.
Keywords: chronic kidney disease; uremic toxins; senescence; Nrf2; ageing
Key Contribution: This review summarises our current knowledge about the molecular drivers of
early vascular ageing (with a focus on vascular calcification) in context of the uremic phenotype
in CKD. We discuss the promising pre-clinical data regarding therapeutic interventions for novel
targets; which includes Nrf2 agonists and senolytic compounds.
1. Introduction
Ageing is characterised by a decline in functional physiological capability over the life course.
The rate of ageing can be manipulated experimentally, however significant, therapeutic intervention to
mitigate physiological decline remains largely limited to pre-clinical models [1]. Ageing is a leading
risk factor for multiple chronic ‘burden of life style’ diseases, including cardiovascular disease (CVD),
osteoporosis, type-2 diabetes, cancer and chronic kidney disease (CKD), which are responsible for
considerable mortality [2]. Baker and Sprott [3] originally postulated that: “A Biomarker of Aging (BoA)
is a biological parameter of an organism that either alone or in some multivariate composite will, in the absence
of disease, better predict functional capability at some late age than will chronological age”. This is relevant to
cellular senescence, a state of cellular growth arrest, as the accumulation of senescent cells in a tissue
or organ restricts health span (Figure 1) [1]. Cellular senescence is one of the hallmarks of ageing that
are common across taxa [1]. It remains unclear, however, whether these hallmarks interact cumulatively,
synergistically or independently. Furthermore, these features may underpin age-related morbidities, but
may be distinct from the morbidity per se. Indeed, it remains undetermined if they act uniformly in context
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across the life course, or if they are subject to the forces of antagonistic pleiotropy [4,5]. Cellular senescence
is also present during mammalian embryonic development, shown to mediate tissue remodelling and cell
balance in the mesonephros and endolymphatic sac, respectively [6]. In similarity with oncogene-induced
senescence, senescence-associated secretory phenotype (SASP) mediators and cell arrest proteins, p21
and p15, are also expressed. It has been suggested that oncogene-induced senescence is an adaptive
mechanism that evolved from developmental senescence [7]. Additionally, in multiple kidney diseases,
senescence biomarkers have been observed in renal tissue [8] and more recently these observations have
been extended to media calcification within the uremic vasculature [9]. Although further research to
better understand potential pathological mechanisms is warranted, it remains to be determined if these
reflect intrinsic features of the specific morbidity, or are a consequence of it.
Chronic kidney disease–mineral bone disorder (CKD–MBD) is characterised as a syndrome of
mineral abnormalities (e.g., calcium, phosphate, vitamin D, etc.); bone abnormalities (relating to strength,
turnover or volume of bone); and vascular calcification (VC), a complication which manifests as early as
CKD stage 2 [10]. Coronary artery calcification is an independent predictor of cardiovascular mortality
in CKD [11], with over 50% of deaths in CKD patients relating to CVD [12]. This reflects a plethora
of detrimental early vascular ageing (EVA) effects, more typical of the vascular environment observed
in the elderly [13]. CKD patients present with a progeric phenotype inclusive of increased allostatic
load, elevated levels of pro-ageing factors, reduced anti-ageing factors and altered anabolic/catabolic
pathways [14,15]. Recent experimental evidence in pre-clinical models has shown that senolytic drugs
(which promote effective removal of senescent cells) prolongs the health span and lifespan in mice by
up to 36% [16], supporting the initiation of preclinical studies with senolytic drugs in the uremic milieu.
Whether this translates into humans remains to be determined [17].
In this review, we will appraise current knowledge of VC, focusing on the tunica media and intima
arterial calcification, as a complication of CKD–MBD; the consequence of dysregulated mineral metabolism
in the uremic milieu, with special reference to elevated serum phosphate levels [18]. We will discuss
evidence surrounding the role of cellular senescence in mediating hydroxyapatite crystal deposition and
the latest advances in therapeutically targeting VC.
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Figure 1. A schematic view of the pathways, molecular mechanisms and cell types inducing cellular 
senescence, thus leading to chronic age-related diseases. C/EBP-β, CCAAT/enhancer binding 
protein-β; IL-1β, interleukin 1β; IL-6, interleukin 6; NF-κB, nuclear factor κB; ROS, reactive oxygen 
species; TGF-β, transforming growth factor β; nuclear factor-erythroid-2-related factor 2, Nrf2. 
Adapted from Tchkonia et al. 2013 [19]. 
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2.1. Introduction to Senescence  
In 1961 Hayflick and Moorhead reported human fibroblasts to have a replication doubling 
potential of 50 (±10) in vitro, otherwise known as the Hayflick limit. They attributed the finding to 
“senescence at the cellular level” [20], and four years later attributed the replication limit to cellular 
ageing [21]. The meaning, relevance and implications of this now seminal finding have evolved over 
the past 50 years. The following section aims to summarise what constitutes cellular senescence, 
before outlining components specific to CKD–MBD.  
Senescence is characterised as a state of irreversible cellular growth arrest, which acts as an 
anti-oncogenic mechanism [22]. Senescent cells are metabolically active but not physiologically 
contributory [8]. Numerous cyto-stressors act as inducers of senescence, including oxidative stress, 
telomere attrition and mutations [19]. Senescent cells can be grouped into distinct classes: 
developmental or oncogene-induced; with key differences relating to function and clearance. 
Developmental senescent cells are induced acutely, and have fundamental roles in tissue growth 
and patterning [7]. However, their contribution to these processes must be viewed through the lens 
of antagonistic pleiotropy [5]. Such cells are transiently present; effectively removed by apoptosis 
[7]. Conversely, oncogene-induced senescent cells are associated with age-related pathologies, 
driven by their detrimental systemic paracrine effects and inability to be effectively removed [8,23]. 
These characteristics have been attributed to two important features of senescence; the SASP and the 
pro-survival senescence cell anti-apoptotic pathways (SCAPs). 
Figure 1. A schematic view of th pat w ys, molecul echanisms and cell types inducing cellular
senescence, thus leading to chronic age-related diseases. C/EBP-β, CCAAT/enhancer binding
protein-β; IL-1β, interleukin 1β; IL-6, interleukin 6; NF-κB, nuclear factor κB; ROS, reactive oxygen
species; TGF-β, transfo ming grow h factorβ; nuclear factor-erythroid-2-related factor 2, Nrf2. Adapted
from Tchkonia et al. 2013 [19].
Toxins 2019, 11, 82 3 of 13
2. Senescence
2.1. Introduction to Senescence
In 1961 Hayflick and Moorhead reported human fibroblasts to have a replication doubling
potential of 50 (±10) in vitro, otherwise known as the Hayflick limit. They attributed the finding to
“senescence at the cellular level” [20], and four years later attributed the replication limit to cellular
ageing [21]. The meaning, relevance and implications of this now seminal finding have evolved over
the past 50 years. The following section aims to summarise what constitutes cellular senescence, before
outlining components specific to CKD–MBD.
Senescence is characterised as a state of irreversible cellular growth arrest, which acts as an
anti-oncogenic mechanism [22]. Senescent cells are metabolically active but not physiologically
contributory [8]. Numerous cyto-stressors act as inducers of senescence, including oxidative
stress, telomere attrition and mutations [19]. Senescent cells can be grouped into distinct classes:
developmental or oncogene-induced; with key differences relating to function and clearance.
Developmental senescent cells are induced acutely, and have fundamental roles in tissue growth
and patterning [7]. However, their contribution to these processes must be viewed through the lens of
antagonistic pleiotropy [5]. Such cells are transiently present; effectively removed by apoptosis [7].
Conversely, oncogene-induced senescent cells are associated with age-related pathologies, driven by
their detrimental systemic paracrine effects and inability to be effectively removed [8,23]. These
characteristics have been attributed to two important features of senescence; the SASP and the
pro-survival senescence cell anti-apoptotic pathways (SCAPs).
2.2. SASP
The SASP is composed of pro-inflammatory, pro-fibrotic and matrix degrading components,
consisting of cytokines, chemokines, proteases and growth factors [24]. Differences in molecules
secreted as part of the SASP have been observed between developmental and oncogene-induced
senescent cells, between different cell types and between cells induced by differential stressors [17].
However, interleukin (IL)-1β, IL-6, plasminogen activator inhibitor 1 and monocyte chemoattractant
protein 1 are highly conserved SASP components [8]. Age-related morbidities have common
underpinning molecular mechanisms [4,5,14], such as persistent low-grade sterile inflammation
(“inflammaging”), increased oxidative stress, immunosenescence, mitochondrial dysfunction and
metabolic imbalances [25]. How much of the inflammatory component of inflammaging is due to
accumulation of senescent cells remains to be proven. Any such relationship may be related to
decreased expression of nuclear factor-erythroid-2-related factor 2 (Nrf2), which is a feature of chronic
‘burden of lifestyle’ diseases [26]. In keeping with such a postulate, genetic depletion of Nrf2 has
been reported to exacerbate age-related induction of senescence markers and pro-inflammatory SASP
factors, resulting in a heightened inflammatory state [27]. However, senescence-associated microRNAs
have been shown to mediate downregulation of Nrf2 in endothelial cells [28], implying the relationship
between senescence and Nrf2 may be bidirectional.
Another important property of the SASP is its ability to induce senescence in surrounding
cells via a bystander effect. This was first demonstrated in vitro, through co-culturing senescent
cells with younger cells, and observing the older cells inflicting DNA damage on neighbouring
cells [29]. The effect occurs via nuclear factor κB (NF-κB) signaling, in the presence of reduced
antioxidant defenses and increased generation of reactive oxygen species [30]. As NF-κB is under
epigenetic regulation by histone deacetylases [5], such as NAD+-dependent sirtuin 1 [31], this suggests
sirtuin 1 agonists, such as resveratrol, may be an attractive therapeutic intervention for ‘burden of
lifestyle’ diseases [5]. Notably, it has already been demonstrated to be effective at reducing VC and
atherosclerosis in mice [32].
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2.3. SCAPs
SCAPs have been termed “the Achilles’ heel of senescent cells”. These are anti-apoptotic
pathways which exert their actions to protect themselves from their own SASP (i.e., recruiting immune
cells to initiate apoptosis) [17]. These include p21, phosphoinositide 3-kinase (PI3K)δ and B-cell
lymphoma-extra large (BCL-xL), which were among the first SCAPs to be identified and targeted with
the senolytic compounds Quercetin and Dasatinib (often used in combination) to selectively induce
apoptosis in senescent cells [33]. Since the original observation, an additional SCAP, based around the
activity of heat shock protein 90, has been identified [34].
2.4. Biomarkers of Cellular Senescence
Finding universal biomarker(s) for senescence is not straightforward [35]. Differing exposomes
and differing life course stages may require different markers to allow for the effects of antagonistic
pleiotropy and lifestyle. Burden of lifestyle diseases may also require a marker(s) that can distinguish
features of ageing per se from features specific to morbidity [5]. Inter-individual differences in
age-related physical capability also are significant and may not accurately reflect the burden of
cellular senescence, due to number and location of senescent cells differentially affecting function
dependent on the organ and tissue in which they reside [36].
The molecular pathways inducing cells to a senescent state are still not fully defined [37]. Indeed,
an accepted description of what actually constitutes senescence at a molecular level remains debated.
Furthermore, various pro-inflammatory cells (e.g., a peritoneal-derived macrophage subpopulation)
can be induced to show some features more typically associated with senescence, such as beta-gal
staining and p16ink4a expression [38]. While this emphasises the need for more specific biomarkers
which fit accepted criteria for a BoA [3], the cognate transcript for p16ink4a termed CDKN2A, has
proven robust in vivo, when applied to measures of age-related physiological function in healthy
tissue. Analysis of renal allografts has shown CDKN2A expression to be a consistently better predictor
of biological age and age-related physiological function than telomere length [39–41].
2.5. Senescence in CKD–MBD
Abnormalities of mineral metabolism in CKD–MBD manifest from progressive loss of renal
function and dysregulated bone metabolism. This gives rise to a toxic uremic milieu, which promotes
vascular smooth muscle cell (VSMC) proliferation, migration, apoptosis, and senescence, further
inducing a premature ageing phenotype in multiple cell types, most notably in arterial and bone
tissue [22]. These clinical sequelae are associated with CVD and osteoporosis, respectively [14].
Compelling novel data suggests that uremia accelerates the accumulation of senescent cells in the
kidney, contributing to a decline in renal function in CKD, while removal of senescent cells restores
renal function in ageing mice [42]. It is also conceivable that the toxic uremic milieu spreads allostatic
load across the body and contributes to senescence of cells in other tissues and organs, such as the
skeleton and vasculature [14].
Both developmental and oncogene-induced senescent cells are present in the kidney over the life
course, with the deleterious chronic class of these cells postulated as being associated with promoting
pathology in acute kidney injury, diabetic nephropathy and CKD–MBD [8]. Oncogene-induced
senescence is present in a variety of cell types in the setting of CKD, including stem cells, endothelial
cells, immune cells, and progenitor cells [43].
In aged mice, osteoclasts, osteoblasts and osteoclast progenitor cells display increased expression
of p16INK4a in comparison to young mice [23]. Moreover, targeting of senescent cells in aged mice
via genetic ablation, SASP inhibitors or senolytic compounds, independently improved bone mass
and bone microarchitecture outcomes in all instances [44]. Although this suggests senescent cells
have a causal role in the pathogenesis of age-related bone loss, this has not yet been studied in the
context of CKD–MBD. The strong independent association between low bone density and increased
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VC [45] implies an inverse relationship between bone mineral density and early vascular ageing (EVA)
associated with arterial stiffening and cardiovascular mortality [46].
3. Calcification
3.1. Introduction to Calcification
Calcification as part of EVA is not a recent observation, being first described in the setting of
renal disease by Virchow in 1855, while VC per se has been described in humans living 5000 years
ago [47]. However, in similarity with senescence, much is still to be learned regarding its aetiology.
Hydroxyapatite crystal deposition can present in the tunica media, intima or cardiac valves,
a complication of CKD–MBD [48] that is strongly associated with high cardiovascular mortality
in this patient population [49]. Furthermore, between 15–20% of calcified vessels and valves are
ossified [50]. Nonetheless, a direct and causal relationship between VC and all-cause/cardiovascular
mortality is not yet proven, as the possibility remains that VC acts as a confounding factor [49].
Traditional Framingham risk factors (e.g., smoking, diabetes, etc.) are insufficient at accounting for
the high incidence of cardiovascular mortality in CKD–MBD, so non-traditional risk factors—such as
abnormal mineral metabolism, oxidative stress, and inflammation—have also been implicated [18].
Differences in the pathogenic mechanisms underlying CKD–MBD, anatomical/histological locations
and clinical outcomes suggests intimal and medial calcification are “distinct entities”; a concept now
widely accepted [48].
As previously stated, CKD is characterised by a persistent low-grade inflammation, with factors
such as dialysis membranes, oxidative stress, microbial factors, uremic toxins, and cellular senescence
contributing to the increased inflammatory microenvironment [51]. Inflammation is also a common
feature of its clinical sequelae; a driving force behind the promotion of EVA. IL-6 and C-reactive protein
are independent predictors of cardiovascular mortality in CKD patients [52,53]. Furthermore, it has
been shown that elevated aortic microinflammation is present both in the absence of calcium and
phosphate, and before hydroxyapatite deposition in the media layer, suggesting a role in the initial
stages of VC [54]. Additional inflammatory components involved in the pathogenesis of tunica media
and intima calcification processes are outlined throughout this section.
3.2. Tunica Media Calcification
Tunica media calcification, also known as Mönckeberg calcification, is associated with arterial
stiffening (arteriosclerosis), sudden cardiac death and reduced perfusion of cardiac tissue. Under
the umbrella term of VC, this entity is most commonly observed in CKD, and constitutes a clinical
hallmark of the disease. Similar to bone formation, media calcification can be partitioned into three
phases: initiation, nucleation and crystal growth [55], as both VSMCs and osteoblasts differentiate
from mesenchymal progenitor cells [47].
The tunica media layer is primarily composed of VSMCs, elastin and collagen [56]. Elastin
degradation is required for the creation of nucleation sites for matrix vesicles (present in the initiation
phase) and the promotion of osteogenic differentiation of VMSCs, through an upregulation of tumour
necrosis factor (TNF) [57]. This process is driven by upregulation of matrix metalloproteinase (MMP)
expression, most notably MMP-2 and MMP-9 [58], which have been described as part of the SASP [59].
TNF also promotes an upregulation of Runt-related transcription factor 2 (RUNX2), an important
regulator of the trans-differentiation of VSMCs, further increasing expression of osteogenic genes,
such as osteocalcin and alkaline phosphatase. This process is further implemented when phosphate
enters VSMCs through sodium-dependent phosphate transporter 1 (PiT-1), facilitating the detrimental
formation of hydroxyapatite crystals in the extracellular matrix [57]. Pit1 blockade and RUNX2
KO mice have been shown to inhibit mineralisation and osteoblast differentiation, respectively,
exemplifying their contribution to VC deposition [60,61]. Circulating vascular cells, mesenchymal
progenitor cells (including monocytes) and pericytes may also be additional sources of cells subjected
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to osteoblast-like trans-differentiation [62]. VSMC apoptosis also promotes VC [63], preceding the
deposition of hydroxyapatite crystals [64].
Physiologically, there is a balance of mineral metabolism inducers (e.g., phosphate, parathyroid
hormone, fibroblast growth factor 23 etc.) and inhibitors (e.g., matrix Gla protein (MGP),
fetuin-A, Klotho etc.) [57]. In the uremic environment the balance is tipped towards a pro-calcific
microenvironment, as levels of inducers are increased and inhibitors reduced, the consequence of
uremic inflammation and oxidative stress, which suppresses expression of Nrf2-Keap1 [65]. Indeed,
animal studies suggest that the Nrf2-Keap1 signaling pathway plays an important role in the VC
process. Yao et al. [66] have reported that activation of the Nrf2 signaling pathway may prevent
hyperphosphatemia-induced VC by inducing autophagy in VSMCs. Moreover, in an in vivo mouse
model, activation of Nrf2 by dimethyl fumarate attenuated Vitamin D3-induced VC [67] and resveratrol
was shown to ameliorate VC by regulation of Nrf2 and Sirtuin 1 [68]. Finally, hydrogen sulfide (H2S),
an endogenous signaling molecule with antioxidant properties, attenuated calcification of VSMCs
via activation of Nrf2/Keap1 [69]. The pathogenic effects of only a minority of inducers/inhibitors
have been demonstrated in vivo in rodent animal models. For example, Klotho-deficient mice show
extensive soft tissue calcification accompanying other premature ageing abnormalities [70]. However,
the relative influences of the majority of uremic toxins may still be unknown [71]. In this context, it is
of interest that Klotho induces Nrf2-mediated anti-oxidant defenses in human aortic smooth muscle
cells [72].
3.3. Tunica Intima Calcification
In contrast to media calcification, cardiovascular outcomes related to intimal calcification are
associated with increased risk of plaque rupture, thereby leading to acute occlusion of vessels [48].
This occurs in medium to large sized arteries on the proximal end of the vascular tree, as opposed
to resistance-sized arteries. Key mechanistic differences drive intimal calcification, when compared
to medial calcification. For example, atherosclerotic plaques are a pre-requisite, as the deposition of
calcium crystals form in the advanced stages of the atherosclerosis [49]. Atherosclerosis, an inflammatory
driven disease resulting from endothelial dysfunction [48] begins with accumulation of low-density
lipoprotein (LDL) in the artery wall, progressing to form a plaque. The plaque evolves from a small
lesion into a clinically dangerous and structurally unstable form [73]. As Nrf2 deficiency promotes
plaque instability in hypercholesterolemic mice [74] it is unsurprising that inflammation plays a more
prominent role in initiating this process. Macrophages, key players in the atherosclerosis process,
release matrix vesicles supplying a nidus for mineralisation within the plaque, and downregulate
matrix Gla-protein (MGP) expression [75]. Macrophages also contribute to pro-calcifying pathways
by expressing osteogenic proteins RUNX2 and bone morphogenetic protein 2 (BMP2) [76]. Moreover,
macrophages are capable of differentiating into osteoclast-like cells, mirroring their mineral resorption
function in VSMCs [77]. VSMCs from the neighbouring medial layer also infiltrate the plaque in
response to the atherosclerotic lesion [49], a source of the osteogenic mediators, as well as circulating
and resident stem cells [78].
However, any clinical significance remains debated. As it has been suggested that calcification
of plaques prone to rupture may stabilise the plaque [79], VC has been regarded as beneficial in
non-renal patients [80]. The clinical implications of this phenomenon in CKD are undetermined,
as plaque stability after microcalcification and macrocalcification may differ. Macrocalcification (or
spotty calcification), promoted by pro-inflammatory M1 macrophages during atherosclerotic plaque
progression, was shown to associate with plaque rupture [81]. Although the exact mechanism(s) of the
M1-mediated process remains to be fully elucidated, pro-inflammatory cytokines TNF and oncostatin
M may promote osteogenesis by upregulation of RUNX2 and alkaline phosphatase. A healing
process is initiated in response, characterised by a phenotypical switch of M1 to M2 macrophages.
The anti-inflammatory actions of M2 macrophages promote the resolution of inflammation and
maturation of VSMCs—hallmarks of macrocalcification, which is associated with plaque stability [82].
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Taken together, the clinical implications of plaque stability are largely dependent on the differential
effects of macrophage polarity.
4. Does Senescence Drive Vascular Calcification?
The bulk of current knowledge, relating to senescence as a cause of EVA, has been derived from
studies of intima calcification. Hence the association between senescence and VC remains unproven
and any findings must be translated to medial calcification with caution. Senescence has been observed
in VSMCs at the site of atherosclerotic plaque, promoting plaque formation and vulnerability [83].
Senescence in vascular endothelial cells, endothelial progenitor cells, and VSMCs has been implicated
in the development and progression of atherosclerosis [84–86]. During the early stages of plaque
initiation in a mouse model of atherosclerosis (Ldlr KO) senescent macrophage foam cell accumulation
was observed in the sub-endothelial space within the artery wall. It has been suggested that senescent
endothelial cells drive atherosclerosis through increased infiltration of oxidized LDLs across a leaky
membrane, or via upregulation of MMPs from the SASP, thereby transitioning stable atheromas
into unstable atheromas [36]. Evidence regarding the involvement of senescent cells in calcification
(i.e., the latter stages of plaque progression) has been reported by Roos et al., [87] through targeting
senescent cells with a genetic elimination strategy and senolytic intermittent therapy (Dasatinib +
Quercetin) in aged and hypercholesterolemic mice. Senolytic treatment reduced senescence markers in
the medial layer of the aorta and reduced aortic calcification in both aged and hypercholesterolemic
mice when compared to vehicle-treated mice. This was also associated with reduced protein levels of
osterix, an established marker of osteogenesis.
Burton et al. [88] have proposed a strong link between VSMC senescence and the progression
of atherosclerosis (plus the development of VC) based on microarray transcriptome analysis. They
demonstrated differential regulation of genes with inflammatory (IL-8, IL-1β, ICAM1, TNFAP3, ESM1,
and CCL2), tissue remodeling (VEGF, VEGFβ, ADM, and MMP-14) and calcification (MGP, BMP2,
SPP1, OPG, and DCN) functions in senescent VSMCs versus non-senescent proliferating VSMCs.
Alique et al. [89] have determined in vitro that plasma microvesicles (MVs) from elderly subjects and
from senescent endothelial cells promote VC in human aortic smooth muscle cells. Senescent human
umbilical vein endothelial cell (HUVEC)-derived MVs and MVs from elderly subjects expressed more
pro-calcification proteins (e.g., annexin A2, annexin A6 and BMP2) and increased calcium content,
when compared to young cells. It has been suggested that differences between contractile and synthetic
VSMCs may reflect their origin, rather than trans-differentiation from a common source [86]. Based
on this hypothesis, findings relating to senescent VSMCs at the site of plaque rupture indicate that
senescence in circulating progenitor cells contribute to the pathology. However, calcification was not
examined in this study [78].
Studies specific to CKD have also been completed, albeit to a lesser degree. We have reported
previously a positive correlation between CDKN2A/p16INK4a and medial calcification in uremic
epigastric arteries. In addition, CDKN2A/p16INK4a and SA-β-Gal expression increased with the degree
of medial calcification, suggesting this may contribute to the pathogenic mechanism(s) underlying
VC [9]. Despite the evidence presented, many questions remain to be answered before a causal
relationship between senescence and EVA can be established. For example, is the senescence and VC
relationship bidirectional, as determined experimentally with inflammation and VC? Inflammation is
a well-defined risk factor underlying the pathogenesis of VC in CKD, however it has been demonstrated
that micro-calcification may drive further vasculature inflammation in carotid arteries, highlighting
the importance of investigating the possibility of senescence as a consequence and inducer of VC [90].
5. Targeting Vascular Calcification Therapeutically
At present, clinical therapeutic interventions to reverse VC remain in development [49]. While
non-calcium phosphate binders can slow VC progression, they are not curative [91]. Targeting some
of the aforementioned inducers and inhibitors, which have been found to be elevated or reduced
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in CKD patients, is an ongoing approach to intervene in disease progression, as seen with vitamin
D supplementation. Analogous to statin therapy and renal transplantation, this approach has not
yielded convincing data on VC regression. Based on the growing body of exciting pre-clinical data,
targeting removal of senescent cells in this context remains a possible avenue for achieving significant
intervention. Senolytic compounds are thus an attractive therapy with the potential to address multiple
‘burden of lifestyle’ diseases where senescence may be an underpinning component. In support of such
a hypothesis, data from Xu et al. [16] has demonstrated prolongation of the lifespan of naturally aged
mice and senescent cell transplanted young mice by 36%, using a senolytic combination of Dasatinib
and Quercetin. The same ‘cocktail’ of senolytic drugs attenuated physical dysfunction and reduced
VC in the aorta of aged and hypercholesterolemic mice when administered long-term [87]. Despite
the promising preclinical findings, a number of unknowns remain, such as undefined side effects and
the optimal time to initiate treatment in the patient. It also remains to be seen if senolytic cocktails
are effective in reducing VC in the uremic toxic milieu with high phosphate and reduced Klotho
expression, as to the best of our knowledge, no such studies have been conducted.
In the aforementioned mouse model studies, the following drug concentrations were used:
5 mg/kg Dasatinib and 10–50 mg/kg Quercetin, or an isovolumic vehicle, via oral gavage [16,87].
Quercetin, a flavonoid with anti-inflammatory actions, can be consumed through diet or
supplementation, however the synergistic actions of Dasatinib and Quercetin combined were shown
to be superior in removing senescent cells than either compound alone [33]. In a phase II clinical trial
for senescence in CKD (currently in its recruitment phase), the intervention arm consists of a daily
dosage of 100 mg Dasatinib and 1000 mg Quercetin [92], equating to 1.43 mg/kg and 14.3 mg/kg
for a 70 kg human, respectively. Future clinical trials will determine the tolerability and efficacy of
concentrations physiologically achievable in humans.
An alternative to the ablation of senescent cells is to target the SASP. Hegner et al. [93] have
ameliorated uremia-induced calcification in vascular progenitor cells in vitro by pharmacologically
blocking pro-inflammatory cytokines. Although markers of senescence were not studied, the known
SASP components TNF and IL-1β were among the cytokines altered. Finally, as activation of the Nrf2
signaling pathway has inhibited VC in several experimental animal models [66,67], the effects of Nrf2
agonists, such as bardoxolone methyl and dimethyl fumarate, on arterial calcification and stiffness
should be tested. As Nrf2 may control different mechanisms involved in the physiopathology of bone
disease [94], Nrf2 activation may also be a novel therapeutic strategy for uremic bone disease.
6. Conclusions
While the involvement of senescence in VC, bone disease, and other ‘burden of life style’ diseases
is beginning to be appreciated from proof-of-concept studies, true causation can only be proven by
randomised double-blind controlled studies. Further research into understanding how risk factors and
inducers drive mechanisms, which result in VC is needed before therapeutic interventions become
a viable option. Prior to this, critical issues of efficacy and safety should be assessed for successful
development and implementation. However, since therapeutics targeting senescent cells and the
Nrf2 signaling pathway are beginning to mature, studies need to be conducted to unravel if these
treatment strategies may offer a novel possibility to interfere with the progeric phenotype that results
as a consequence of CKD.
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